In breast cancer, Tumor-derived sEVs transport miR-122 to decrease the glycolytic utilization in matrix cells by targeting PKM2, making tumor cells at pre-metastatic sites use glucose to the maximum extent [96]. The gene discussed is PKM; the disease is neoplasm.